MYCN and neuroblastoma: We are interested in defining these co-operating lesions, in addition to identifying oncogenic lesions that contribute to neuroblastoma tumourigenesis or progression independent of MYCN. Activating mutations in Ras family genes have been identified in 30% of human cancers [6].